ABT-263 induced tumor cell killing transiently in only one of three LTED-selected ERα+ breast cancer cell lines tested, but this response was not sustained, and ABT-263 did not decrease tumor cell growth in culture or in vivo (Fig. 1e–h). This evidence concerns the gene ESR1 and breast cancer.